Key result
Asparaginase therapy resulted in a peak triglyceride level of 465 mg/dL, significantly higher than the baseline of 108 mg/dL, with 67% of patients exceeding 200 mg/dL during treatment.
Why the study?
Does asparaginase therapy cause lipid abnormalities in children with acute lymphoblastic leukemia?
Population
Children with acute lymphoblastic leukemia (ALL), including newly diagnosed patients and long-term survivors
Comparison
Asparaginase therapy vs Before and after asparaginase therapy, and…
Design
Cohort
Authors
Loading...
Asparaginase-associated hypertriglyceridemia is common yet transient in pediatric ALL; leaves open optimal monitoring thresholds and cardiovascular implications.
Does asparaginase therapy cause lipid abnormalities in children with acute lymphoblastic leukemia?
Asparaginase therapy in children with ALL is associated with a striking but transient increase in triglyceride levels, which generally does not require therapy modification unless levels exceed 2,000 mg/dL.
Parsons et al. (1997) studied this question. Asparaginase therapy resulted in a peak triglyceride level of 465 mg/dL, significantly higher than the baseline of 108 mg/dL, with 67% of patients exceeding 200 mg/dL during treatment.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: